microRNA Testing for Identification of Personalized Weight Management
NCT ID: NCT04217850
Last Updated: 2022-05-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
26 participants
INTERVENTIONAL
2020-01-13
2020-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Weight Tracking and Weight Loss Outcomes: Establishing the Standard of Care
NCT01646086
Personalized Lifestyle Intervention and Weight Control
NCT04079972
Time-restricted Eating and High-intensity Interval Training for Metabolic Health in Adults With Overweight/Obesity
NCT07036562
Sustaining the Reach of a Scalable Weight Loss Intervention Through Financial Incentives
NCT04225234
Choosing Healthy Options in College Environments and Settings
NCT01134783
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A major barrier that prevents the use of miRNAs in weight loss interventions is the inability of accurately quantifying miR-140 and 935 levels in blood samples. To minimize the miRNA contamination from red-blood cell lysis, miRNA analysis must be performed within 30 minutes of blood draw. Current miRNA detection and quantification technologies take hours/days to quantify miRNAs, require bulky equipment, and are expensive. In addition, current miRNA detection methods do not have sufficient sensitivity, detection span and specificity for clinical sample analysis. To address this need, PI. Nawarathna has recently developed a highly sensitive disposable miRNA sensor that can quantify miRNAs in point-of-care settings within 15 minutes with an assay cost of $50 per test. However, the effectiveness of the developed miRNA sensor to accurately quantify the variations of target miRNA levels (miR-140 and 935) pre- and post-diet and exercise intervention is unknown.
The objective of the proposed work is to investigate the efficacy of this miRNA sensor as a potential diagnostic device in weight management. If successful, the impact of proposed the research is two-fold: first, development of a point-of-care diagnostic device (miRNA sensor) for providing a personalized strategy for weight management (diet and exercise or bariatric surgery) and second, ability to immediately expand miRNA detection to measure other factors that can impact overall well-being (e.g.: mental and emotional health, stress, and fatigue) and diseases (e.g.: cancer, cardiovascular diseases, and others). The objective of the proposed research will be achieved through following this specific aim:
Aim: To investigate if the miRNA sensor is capable of identifying individuals who will consistently lose weight with energy restricted diet and exercise intervention.
The proposed research will develop a pilot study with overweight individuals as participants. Subjects will participate in the diet and exercise intervention for 12 weeks and miRNA analysis will be performed at 3 time points during the intervention (pre-mid-post). We will then investigate the effectiveness of the sensor.
The miRNA sensor technology, once fully developed, will be similar to a finger prick glucose monitor. Once commercially available, miRNA sensors can be purchased and used for diagnostic applications in clinics or self-testing at home or remote and rural area clinics and hospitals. Therefore, the outcomes will fundamentally advance how the individualized weight management method is selected. For this reason, this research has a positive translational impact on human health.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
500 kcal Energy Deficit
The goal of the nutrition and exercise intervention will be to induce an energy deficit of approximately 500 kcals/day over the 12-week period in order to induce an approximate 5% weight loss in all participants.
250 kcal Dietary Energy Restriction
The nutrition intervention will be individualized and implemented as a free-living energy-restricted eating plan where energy intake will be based on a mild restriction (approx. 250 kcal/day).
Aerobic Exercise
Supervised aerobic exercise will be combined with the energy restriction. Individuals will perform aerobic exercise (treadmill, cycle, or rower or combination) 4-5 days per week for 12 weeks. At each session they will expend 250 or more calories to further meet or exceed the 500 kcal energy deficit.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
250 kcal Dietary Energy Restriction
The nutrition intervention will be individualized and implemented as a free-living energy-restricted eating plan where energy intake will be based on a mild restriction (approx. 250 kcal/day).
Aerobic Exercise
Supervised aerobic exercise will be combined with the energy restriction. Individuals will perform aerobic exercise (treadmill, cycle, or rower or combination) 4-5 days per week for 12 weeks. At each session they will expend 250 or more calories to further meet or exceed the 500 kcal energy deficit.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* body mass index 25-34.9
* able to do physical activity and exercise
Exclusion Criteria
* pregnant,
* currently use any nicotine product
* diagnosed neuromuscular disease
* diabetes,
* uncontrolled high blood pressure,
* diagnosed cancer,
* previously had a heart attack or other chronic heart related conditions that are not controlled with medicine
* difficulty moving without assistive devices or walking one-quarter mile
* are taking medications that influence muscle size (testosterone, growth hormone, etc.),
* have had bariatric surgery
* have a body mass greater than 350lbs,
* fear blood, blood draws, or needles
* adverse reaction to a blood draw in the past.
18 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
North Dakota State University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
North Dakota State University
Fargo, North Dakota, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EN20014
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.